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Background 
Stroke survivors frequently report unmet needs in the longer term but there is 
limited evidence to guide provision of on-going rehabilitation.  
 
Methods 
This study was a randomised controlled trial involving 19 UK centres which 
provided ESD. Adult stroke patients were individually randomised to receive 
EXTRAS or usual care (1:1). EXTRAS involved five rehabilitation reviews 
provided by an ESD team member between one and 18 months post-ESD. 
Reviews consisted of a semi-structured assessment of rehabilitation needs 
followed by goal setting and action planning. The primary outcome was 
performance in extended activities of daily living (Nottingham Extended 
Activities of Daily Living (NEADL) scale) at 24 months. Secondary outcomes 
included satisfaction with services, QALYs and costs. Analyses were ‘intention 
to treat’.   
 
Results/Findings 
573 participants were randomised (EXTRAS n=285, usual care n=288). Mean 
24 month NEADL scores were EXTRAS 40.0 (SD 18.1) and usual care 37.2 
(SD 18.5) giving an adjusted mean difference of 1.8 (95% CI -0.7 to 4.2). At 
24 months patients in the intervention group were more satisfied with the 
services they received (97.7% vs 87.5%, difference 10.2% (95% CI 5.3 to 
15.0)). EXTRAS provided more QALYs (0.07, 95% CI 0.01 to 0.12) and when 
combined with costs, there was a 90% chance of EXTRAS being cost-
effective at conventional thresholds of willingness to pay (£20,000 per QALY). 
 
Conclusion 
EXTRAS did not improve stroke survivors’ performance in extended activities 
of daily living. However, due to the impact on costs and QALYs, EXTRAS has 
a high probability of being cost-effective at conventional thresholds of NHS 
willingness to pay. 
  
 
